Protein transduction domains (PTDs), both naturally occurring and synthetic, have been increasingly employed to deliver biologically active agents to a variety of cell types in vitro and in vivo. In addition to the previously characterized arginine-rich PTDs, including Tat (transactivator of transcription), Antp (Antennapedia) and PTD-5, we have demonstrated that lysine and ornithine, as well as arginine, homopolymers are able to mediate transduction of a wide variety of agents. To screen for optimal PTDs, we have used as a therapeutic cargo a peptide derived from IKK {IκB [inhibitor of NF-κB (nuclear factor κB)] kinase} β, able to bind to the IKK regulatory subunit [NEMO (NF-κB essential modulator)], preventing formation of an active kinase complex. This peptide, termed NBD, is able to block activation of NF-κB, but not basal activity. We demonstrate that PTD-mediated delivery of NBD using certain PTDs, in particular 8K (octalysine), is therapeutic following systemic delivery in murine models of inflammatory bowel disease, diabetes and muscular dystrophy. In addition, we have developed a peptide phage display library screening method for novel transduction peptides able to facilitate tissue-specific internalization of marker protein complexes. Using this approach, we have identified transduction peptides that are able to facilitate internalization of large protein complexes into tumours, airway epithelia, synovial fibroblasts, cardiac tissue and HEK-293 (human embryonic kidney) cells in culture and/or in vivo.
charged cationic PTDs, since they are the most efficient and the best characterized.
Since the reports published simultaneously in the late 1980s that the HIV-1 Tat (transactivator of transcription) protein was able to cross the plasma membrane and the subsequent mapping of this activity to the 11-amino-acid Tat PTD, the field of protein transduction has rapidly gained prominence as an efficient method to modify cellular function in the absence of ectopic gene expression [10, 11] . Protein transduction is rapid and titratable, with a broad range of transducible cell types and tissues. Shortly after the characterization of Tat PTD, another PTD was identified within the Drosophila Antennapedia protein, termed penetratin or Antp [12] . Both Antp and Tat PTDs contain numerous cationic amino acids, or basic residues, which play a crucial role in their transduction properties. These positively charged particles interact with the negatively charged cell membrane which mediates uptake. Studies have suggested that the transduction potential of these peptides is due to their amphipathic helical three-dimensional structure, in which basic residues are directed outward from one face and hydrophobic residues are positioned on the other face [13] . However, the fact that peptides containing a minimum number of arginine or lysine residues work as efficiently as Tat PTD suggests that the charge of the peptide is the main feature of PTDs (see below).
Initial binding of the cationic PTDs to cells is mediated through extracellular glycosaminoglycans. Using membrane glycosaminoglycan-deficient cells or adding free heparin to cell cultures effectively decreases the transducing capabilities of PTDs. In contrast, treating cells low in glycosaminoglycans with dextran sulfate enhances protein transduction [14] . Therefore it is generally accepted that PTDs bind glycosaminoglycans, specifically heparan sulfate, and then transduce cells through a mechanism of receptor-independent, but possibly energy-dependent endocytosis. Several mechanisms have been suggested to explain the second phase of transduction of PTDs, and it is still unknown whether all peptides transduce cells via the same mechanism. The fact that transduction can occur in an energy-independent manner, albeit at a reduced level, suggests that there may be at least two independent mechanisms.
Studies evaluating Tat protein transduction have yielded results consistent with a mechanism of receptor-independent macropinocytosis associated with lipid rafts. Tat uptake is inhibited after treatment with two macropinocytosis inhibitors: cytochalasin D and amiloride. Furthermore, β-cyclodextrin, which depletes cell-surface-associated cholesterol, also inhibited PTD transduction, thereby elucidating the role of lipid rafts. This same investigation showed that dynamin blockade, which would inhibit clathrin-and calveolar-mediated endocytosis, had no significant effects on PTD uptake [15] . However, other studies suggest caveolae-dependent mechanism of PTD uptake, since two caveolae endocytosis inhibitors, nystatin and fillipin, reduced transduction [1] . However, the exact mechanism of uptake may be dependent not only on the PTD itself, but also on its cargo [16] .
Characterization of transduction efficiency
We have characterized previously a panel of positively charged PTDs for their ability to transduce different cell types in culture. We have shown that peptides containing six to eight arginine, lysine or ornithine residues are highly effective for delivery of fluorescent markers or a β-galactosidase fusion protein through a receptor-independent pathway [17] . In particular, 8K (octalysine) was the most effective for transduction of fibroblasts and epithelial cell lines in culture. However, these studies, as well as the majority of other studies evaluating PTD sequences that examine cellular uptake, biodistribution and endosomal escape, have used PTDs carrying fluorescent cargoes. While this approach offers insight into the mechanism of PTD action and allows for examination of transduction efficiency, it provides very little information about the potential for therapeutic application of this technology. Therefore we chose recently to evaluate PTDs functionally by examining various PTD sequences linked to a biologically relevant peptide cargo which, when present intracellularly, can inhibit the NF-κB (nuclear factor κB) signalling pathway.
NF-κB is regarded as a central immunological pathway, which has been implicated in numerous autoimmune and inflammatory diseases. This includes, but is not limited to, RA (rheumatoid arthritis), both Type 1 and Type 2 diabetes mellitus, IBD (inflammatory bowel disease), heart disease, and multiple sclerosis [18] . A variety of inflammatory signals stimulate the NF-κB pathway by activating the IKK [IκB (inhibitor of NF-κB) kinase] complex, comprising three subunits, including the IKKγ regulatory subunit and two catalytic subunits, IKKα and IKKβ. The interaction of these subunits allows for phosphorylation of IKKα and IKKβ, resulting in activation of kinase activity and subsequent phosphorylation of IκB [19] . After phosphorylation, IκB is subsequently degraded which releases NF-κB and reveals a nuclear localization signal, allowing NF-κB to shuttle to the nucleus and activate pro-inflammatory genes ( Figure 1 ).
An 11-amino-acid sequence has been identified within IKKβ comprising the domain in IKKβ that binds to IKKγ [8] . This peptide, known as the NBD [NEMO (NF-κB essential modulator)-binding domain], is able to block the interaction of IKKα and IKKβ with the regulatory subunit IKKγ (NEMO). When this short peptide sequence, TALDWSWLQTE, was linked to Antp PTD, it was able to inhibit IKK/NF-κB signalling in tissue culture and in animal models in a dose-dependent manner. Although there are numerous small-molecule inhibitors of NF-κB, there are some distinct advantages of the NBD peptide. The site of action is highly defined, and, owing to this specific target, only activated, but not basal, levels of NF-κB are inhibited. Also, because of the high specificity of the NBD peptide sequence, it is unlikely to affect other essential kinases, which is not the case for other more general NF-κB inhibitors [20] .
We initially tested a panel of PTD-NBD fusion peptides ( Figure 2 ) for their ability to inhibit IL (interleukin)-1β-induced NF-κB transcriptional activity. In culture, delivery of NBD with Tat, Antp and PTD-5 resulted in the most effective inhibition of IL-1β-induced NF-κB activity. This result is in contrast with in vivo analysis in a murine footpad DTH (delayed-type hypersensitivity) model where 8K and 6R (hexa-arginine), two synthetically derived cationic peptides, worked far more efficiently in blocking footpad swelling following local injection. In the DTH model, injection of Tat-NBD and Antp-NBD was significantly less effective in inhibiting footpad swelling. Although the reasons for the difference in activity observed in cell culture and in vivo are unclear, we speculate that it is due to the ability of 8K and 6R PTDs to efficiently transduce the appropriate target cells, probably antigen-presenting cells, in vivo for conferring the ability to block footpad swelling on the observed anti-inflammatory cells.
Treatment of murine disease models with 8K-NBD
Given that the 8K-NBD peptide was the most effective, we examined the efficacy of this peptide in four murine models of inflammatory disease, Type I diabetes, CIA (collagen-induced arthritis), IBD and DMD (Duchenne muscular dystrophy), that have a documented role for NF-κB in their pathophysiology.
Diabetes mellitus (Type 1 diabetes)
NF-κB, a potent mediator of inflammatory responses, has been associated with various aspects of immunobiology such (e) Finally NF-κB dimer p65p50 is released and then translocates to the nucleus whereby it transcribes pro-inflammatory genes (f).
Figure 2 Structure of the PTD-NBD peptides tested
The different PTDs were fused to NBD through a di-glycine (GG) spacer.
as DC (dendritic cell) development [21] [22] [23] [24] [25] [26] , and significantly reduces the number of myeloid DCs as shown by targeted deletion of the relB gene in mice [27, 28] . IKK has been shown to be activated in NOD (non-obese diabetic) DCs, resulting in hyperactivation of NF-κB, leading to increased production of IL-12 by NOD DCs [29] . Subsequently, the increased IL-12 may be a contributing factor in the apparent skewing toward Th1 subset development [30] . Moreover, increased capacity of IL-12 secretion in NOD mice leads to multiple developmental and functional defects in macrophages [29, [31] [32] [33] [34] .
It has been reported that DCs and macrophages are an early source of TNFα (tumour necrosis factor α) in the NOD islet infiltrate, which may be a key contributing factor for the initiation of β-cell destruction [34] [35] [36] [37] [38] [39] . In addition, NF-κB-binding sites are found in the promoters of critical genes for DC function, such as IL-12 p40 and MHC class II molecules [40, 41] . Furthermore, NF-κB is activated by a number of stimuli encountered by DC and macrophages such as IL-1, TNFα and LPS (lipopolysaccharide) [25, 29, [42] [43] [44] , and DCs primed with Th1 cytokines accelerated the progression of diabetes in neonatal NOD mice [45] .
Based on the observations that NF-κB activation in DC and macrophages has been linked to diabetes, we examined the ability of the 8K-NBD to prevent the onset of diabetes in NOD mice. Female NOD mice (4-week-old) were injected once or twice weekly i.p. (intraperitoneally) with 10 mg/kg 8K-NBD peptide and the onset of hyperglycaemia was measured weekly. We observed that treatment of the mice twice per week with 8K-NBD significantly prevented the onset of diabetes in these young mice and that even treatment once per week reduced the incidence of diabetes. Analysis of the mechanism of action of the peptide has revealed inhibition of NF-κB activation in the splenocytes of the treated mice compared with controls. However, there appears not to be induction of tolerance since the treated mice develop disease shortly after cessation of treatment.
Inflammatory bowel disease
We have also evaluated the effects of 8K-NBD in a mouse model of murine colitis, the IL-10-deficient mouse. Numerous groups have described an overactive NF-κB pathway in humans with both Crohn's disease and colitis, the two variations of IBD [46] . NF-κB activation localized to the inflamed colon has been implicated in mouse models of colitis. Furthermore, these mice have increased levels of inflammatory cytokines, including IFNγ (interferon γ ), IL-12p70, IL-23 and TNFα [47] .
Most previous animal studies examining NBD have been induced T-cell disease models. However, the IL-10-deficient model is more of an innate naturally occurring disease model. By 8 weeks of age, 80% of IL-10-deficient mice have clinical evidence of colitis [48] . Therefore, to evaluate the efficacy of PTDs to treat systemic diseases stemming from a genetic defect in immune function, we treated IL-10-deficient mice at 10-12 weeks of age to evaluate the efficacy of NF-κB inhibition after onset of disease (J. Tilstra, K.K. Rehman, P.D. Robbins and S.E. Plevy, unpublished work).
After 2 weeks of treatment, we saw evidence of gross histological changes accompanied by microscopic changes. These microscopic changes, which included mononuclear cell infiltration, epithelial damage, hyperplasia and ulceration, were significantly decreased after 2 weeks of treatment with the 8K-NBD. Furthermore, these histological changes were accompanied by decreased inflammatory cytokines, including TNFα and IL-12. In this same series of experiments, we evaluated the biodistribution of the peptides and found high levels within the mesenteric lymph node and spleen within 30 min of dosing. These two organs have been shown to play an immunological role in IBD and present a possible mechanism of how the anti-inflammatory, 8K-NBD, treatment worked quickly and effectively.
Collagen-induced arthritis
Initial studies examined the efficacy of NBD by evaluating Antp-NBD peptide in the treatment of a murine model of CIA. In this model, DBA1 mice are sensitized to collagen type II and then subsequently boosted with collagen at day 21. The mice then develop pathologies in their paws, starting at day 28. This disease mimics human RA and shares features which include infiltration of inflammatory cells, joint swelling and release of inflammatory cytokines including TNFα and IL-1β. Delivery (i.p.) of Antp-NBD was reported to significantly reduce the severity of disease and block bone loss in the CIA model if administered starting at day 21 [20, 49] . We have examined the efficacy of the 8K-NBD if administered i.p. starting at day 21, day 28 or day 32. Our results have shown that treatment starting at day 21, before disease onset, significantly reduced disease, similar to what has been reported with Antp-NBD. In contrast, only a marginal reduction was observed when treatment was started at day 28, the time of disease onset, and no significant effect was observed when treatment was initiated following disease onset at day 32. These results suggest that targeting IKK with the NBD peptide may be therapeutic at early stages of disease (CIA model), but not for late-stage disease.
Muscular dystrophy
DMD is a lethal X-linked disorder that results from dystrophin deficiency, involving chronic skeletal muscle inflammation and degeneration. It has been reported that the IKK/NF-κB pathway is elevated in immune cells and regenerative muscle fibres in human DMD and in the mdx mouse model. Interestingly, a mdx NF-κB p65 −/+ mouse has improved pathology and muscle function, and treatment of mdx mice with an Antp-NBD fusion peptide resulted in improved pathology [50] . Given that these results suggest that the IKK/NF-κB signalling pathway is a potential therapeutic target for DMD, we have compared the therapeutic effects of 8K, Tat and Antp-NBD fusion peptides in mdx mice. Treatment of mdx mice three times a week at a dose of 10 mg/kg starting at 3 weeks of age resulted in improved muscle regeneration and pathology with the 8K-NBD and Tat-NBD peptides, both showing enhanced therapeutic activity over Antp.
Conclusions
Overall, our studies have shown that cationic peptides, specifically peptides containing six to eight arginine and/or lysine residues, are very efficient for transduction of different cell types through a mechanism involving binding to heparan sulfate. Moreover, we have used a peptide able to block kinases integral to the inflammatory activation of the NF-κB pathway as both an assay for PTD-mediated delivery and as a therapeutic agent in several murine models of diseases. We demonstrate that, in vivo, the 8K-PTD is the most effective for blocking inflammation in a murine DTH model. This is in contrast with Tat and Antp, which are the more effective for delivery of NBD to block IL-1β-mediated induction of NF-κB in HEK-293 (human embryonic kidney) cells in culture. In particular, we have demonstrated that the 8K-PTD is highly effective in treating murine models of IBD, arthritis and muscular dystrophy without apparent toxicity. Although the exact cell targets for the 8K-NBD peptide in vivo for conferring the significant therapeutic effects are unknown, we speculate that the peptide is efficient at transducing and inhibiting IKK in macrophages and DCs, resulting in suppression of inflammation. Taken together, our results clearly demonstrate differences in efficacy between PTDs in vivo, and that transduction efficiency in culture does not necessarily reflect efficacy in vivo. Moreover, our results clearly demonstrate the ability of PTDs to deliver small peptides which dramatically improve disease in murine models. These findings should lead to the development of clinical trials using the 8K-NBD peptide.
